Tokio Marine Asset Management Co. Ltd. Buys 326 Shares of Illumina, Inc. (NASDAQ:ILMN)

Tokio Marine Asset Management Co. Ltd. grew its stake in Illumina, Inc. (NASDAQ:ILMN) by 7.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,978 shares of the life sciences company’s stock after acquiring an additional 326 shares during the period. Tokio Marine Asset Management Co. Ltd.’s holdings in Illumina were worth $649,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of ILMN. Versant Capital Management Inc raised its position in Illumina by 292.9% in the 2nd quarter. Versant Capital Management Inc now owns 330 shares of the life sciences company’s stock worth $34,000 after purchasing an additional 246 shares during the last quarter. Industrial Alliance Investment Management Inc. acquired a new position in shares of Illumina during the second quarter valued at $34,000. Massmutual Trust Co. FSB ADV lifted its stake in shares of Illumina by 65.1% during the third quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock valued at $56,000 after acquiring an additional 168 shares during the period. Itau Unibanco Holding S.A. bought a new position in Illumina in the second quarter valued at about $61,000. Finally, Mizuho Securities Co. Ltd. bought a new stake in Illumina during the 2nd quarter worth about $63,000. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Price Performance

Shares of NASDAQ ILMN opened at $135.05 on Friday. The company has a fifty day moving average price of $139.66 and a 200 day moving average price of $124.30. The firm has a market cap of $21.42 billion, a PE ratio of -13.56 and a beta of 1.13. The company has a current ratio of 2.43, a quick ratio of 1.85 and a debt-to-equity ratio of 0.94. Illumina, Inc. has a 1-year low of $92.69 and a 1-year high of $156.66.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.26. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The company had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.08 billion. During the same period in the prior year, the firm earned $0.33 earnings per share. Illumina’s revenue for the quarter was down 3.5% compared to the same quarter last year. Research analysts predict that Illumina, Inc. will post 4.11 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on ILMN. JPMorgan Chase & Co. raised their target price on shares of Illumina from $125.00 to $140.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Scotiabank lowered their target price on shares of Illumina from $176.00 to $164.00 and set a “sector outperform” rating for the company in a report on Thursday, August 15th. Morgan Stanley restated an “equal weight” rating and issued a $156.00 price target on shares of Illumina in a research report on Tuesday, November 12th. Daiwa America upgraded Illumina to a “strong-buy” rating in a report on Friday, August 16th. Finally, UBS Group increased their target price on Illumina from $133.00 to $145.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, fourteen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $164.00.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.